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STRUCTURED ABSTRACT 
Aims: 
To assess whether a strategy of invasive management without stents in selected acute 
coronary syndrome (ACS) patients with a large thrombus burden (LTB) might be feasible and 
safe.  
Methods and results: 
We performed a prospective non-randomised observational cohort study of invasive treatment 
decisions guided by optical coherence tomography (OCT) in selected ACS patients with LTB. 
Among 852 ACS patients who had undergone invasive coronary angiography, 101(11.8%) 
patients with large thrombus burden on initial angiography underwent thrombectomy to 
restore TIMI-3 flow without stenting. All of these patients then had repeat angiography with 
OCT (Day 0-2 (Group1), Day 3-6 (Group2) or Day 7-30 (Group3)).  
No adverse events occurred between the initial and second angiograms. Residual thrombus 
was detected in 68% of patients with OCT (respectively, 94%, 79% and 32% in Group1, 
Group2 and Group3) and 20% of cases with angiography. Plaque rupture was detected by 
OCT in 65% of cases. Minimal lumen area was 2.81mm2, 3.40mm2 and 4.89mm2 in Group1, 
Group2 and Group3, respectively. 62% of patients were stented (respectively, 76%, 61% and 
50%). During a minimum follow-up period of 12 months in all patients, 1 non-fatal MI 
occurred and 1 PCI was performed for angina.  
Conclusions: 
Medical management without stents is safe and feasible in selected ACS patients with LTB. 
OCT revealed culprit lesion characteristics that were not disclosed by angiography and 
facilitated treatment decisions.  
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CONDENSED ABSTRACT 
 
We assessed the feasibility and safety of invasive management and selected stenting or not, as 
guided by angiography and OCT, in ACS patients with LTB. In a 2-stage strategy, 
angiography was used to select patients for delayed stenting, and in the second procedure 
angiography and OCT were used to decide on stenting or not. OCT improved the assessment 
of culprit lesion characteristics and thrombus burden. Of 101 STEMI patients, 38% did not 
receive a stent. There were no adverse events related to OCT and only 2 non-fatal MACEs 
occurred during 12 months of follow-up.  
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ABBREVIATIONS LIST 
ACS : acute coronary syndrome 
BMI : body mass index 
BMS : bare metal stent 
CPK : creatine phospho kinase 
DES : drug eluting stent 
IVUS : intravascular ultrasound 
LAD : left anterior descending coronary artery 
LCX : left circumflex 
LMWH : low molecular weight heparin 
LTB : large thrombus burden  
LVEF : left ventricular ejection fraction 
MACE : major adverse cardiac event  
MLA : minimal lumen area 
NSTEMI :non ST segment elevation myocardial infarction 
OCT : optical coherence tomography 
OFDI : optical frequency domain imaging 
PCI : percutaneous coronary intervention 
QCA : quantitative coronary angiography 
RCA : right coronary artery 
STEMI : ST segment elevation myocardial infarction 
TIMI : thrombolysis in myocardial infarction 
 6 
INTRODUCTION 
Early invasive management in patients with an acute coronary syndrome (ACS) is 
supported by evidence-based clinical guidelines1,2 guidelines and overall, prognosis has 
improved in recent years3. In ACS patient treated with PCI, stenting is almost always 
performed4 . 
The purpose of stenting is to prevent acute vessel closure after reperfusion5. However, 
although stenting is routinely performed, stents can cause complications acutely (e.g. distal 
embolization, stent thrombosis) and in the longer term (e.g. restenosis and late/very late stent 
thrombosis). In ACS patients, coronary thrombus is a consequence of plaque rupture and 
persistent or large coronary thrombus (LCT) is a risk factor for adverse outcome after 
percutaneous coronary intervention (PCI) with stenting6. Stent deployment in a thrombotic 
lesion may dislodge thrombus leading to microcirculatory embolization with a no-reflow 
effect on reperfusion7, which is a cause of heart failure acutely and in the longer term. 
Furthermore, stent outcomes may be sub-optimal in thrombotic lesions due to malapposition 
of the stent on the coronary wall, and stent malapposition may also lead to adverse outcomes 
in the longer term. Large Thrombus Burden (LTB) (defined as a thrombus with length more 
than twice the diameter of the coronary artery by Sianos et al) is also associated with an 
increased risk of late stent thrombosis8. Reduction of thrombus burden during PCI improves 
procedure-related outcomes and is recommended in clinical guidelines. For example, the 
TAPAS study9 showed that mechanical thrombectomy improved myocardial blush and 
reduced the rate of 30-day major adverse cardiac events (MACE)10,11.  
We questioned whether stenting could be safely avoided in selected patients with LTB 
and therefore potentially obviate the risk of complications associated with stenting. Given the 
emergence of new anti-thrombotic treatments and improved lesion assessment with intra-
vascular imaging techniques, such as optical coherence tomography (OCT)12, we reasoned 
that stenting may not be mandated in all patients. OCT is a high-resolution (10 µm) 
endocoronary imaging technique based on near-infrared light. It provides fine in vivo analysis 
of the 3-layer structure of the arterial wall13, and of atherosclerotic lesions14 and highly 
sensitive thrombus detection15. OCT has been used since 2005 for imaging ACS-culprit 
lesions16,17 and for immediate18 and late (neointimal cover19,20) post-procedural stent follow-
up. 
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The present study concerned the feasibility, safety and clinical utility of OCT-guided 
treatment decisions in ACS patients during routine clinical practice. Our rationale was that 
detailed assessment of thrombus and culprit lesion characteristics by high-resolution 
endocoronary imaging could guide treatment decisions for coronary stenting after thrombus 
aspiration. 
MATERIAL AND METHODS 
Methods 
Eligible patients  
Between January 2010 and November 2011, 852 patients were admitted for ACS in 
two French hospital centers (Clermont-Ferrand University Hospital Center and Marie 
Lannelongue Surgical Center, Plessis-Robinson). One hundred and one ACS patients were 
included in the present observational study. 
The inclusion criteria were the following: 
- age ≥18 years; 
- STEMI or NSTEMI with high risk clinical characteristics including recurrent 
symptoms, tachycardia, hypotension or heart failure, according to European guidelines21; 
- lLarge thrombus burden (thrombus length more than twice arterial diameter) 
on initial angiography, whatever the initial TIMI flow; 
- aA culprit coronary artery amenable to OCT imaging (including vessel 
diameter <5 mm without significant tortuosity or calcification that might restrict the optical 
catheter). 
The exclusion criteria were the following (at least 1): 
 - pregnancy or breast-feeding;  
 - contra-indication for glycoprotein (GP) IIb/IIIa inhibitor (abciximab, 
eptifibatide or tirofiban); 
 - admission for cardiac arrest;  
 - cardiogenic shock;   
 - known creatinine clearance < 30 ml/min 
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 All patients received treatment with 250 mg of aspirin, a loading dose of 
clopidogrel (600 mg) or prasugrel (10 mg) and therapeutic anti-coagulation (unfractionated 
(50/kg or low molecular weight heparin (1mg/kg)).  
 
Protocol for treatment decisions 
A flow chart which summarizes the decision pathway is shown in Figure 1.  The timing of the 
OCT procedure was at the operator’s discretion during the first month after the acute phase.  
Medical management protocol 
The initial objective was to achieve optimal reperfusion by thrombus aspiration 
(Export Aspiration Catheter, Medtronic, Minneapolis, Minnesota) and treat the patients with 
optimal medical therapy including aspirin, a loading dose of clopidogrel or prasugrel and a 
bolus of abciximab in line with clinical guidelines1.  
Optimal reperfusion was defined in presence of TIMI flow =3 associated with regression of 
pain and >50% reduction in ST elevation at the post-intervention ECG. 
Coronary stenting was indicated when 1 or more of these characteristics were absent. 
Alternatively, when optimal coronary reperfusion was achieved, the treatment decision (based 
on a second angiogram and OCT analysis) could, at the operator’s discretion, be immediate or 
else postponed to allow time for the beneficial effects of optimal anti-thrombotic therapy, 
including dual anti-platelet therapy, glycoprotein IIbIIIa inhibitor therapy and anti-
coagulation with low molecular weight heparin. 
Three study groups were defined according to the timing of repeat OCT imaging: Acute OCT 
(days 0-2), Early OCT (days 3-6) and Late OCT (days 7-30). The different time-points (acute, 
early and late) were pre-defined in order to assess the relationship between the interval from 
the initial angiogram (and duration of anti-thrombotic therapy) vs. culprit lesion morphology, 
as revealed by OCT. 
The indication for a stent was based on a stenosis >70% or plaque prolapse as revealed 
by OCT. The three criteria required to define plaque prolapse were (1) an appearance of a 
mobile plaque in continuity with the coronary wall with (2) evidence of plaque prolapse into 
the lumen and (3) a maximal plaque length exceeding one-third of the arterial diameter. 
All patients received optimal medical therapy, and including some patients who did not 
receive a stent and instead received optimal medical therapy alone.  
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When PCI with stenting was performed, OCT was used to assess the final stent result 
including for stent malapposition, defined as a strut/wall distance greater than the thickness of 
the strut (including polymer if any)22,23, significant intra-stent thrombotic protrusion 
(intraluminal tissue protrusion forming an arch between the stent struts22,23, considered 
moderate when less than and significant when more than 500 µm thick) or proximal/distal 
edge dissection (upstream or downstream: edge dissection).  
Invasive management protocol 
The treatment decision algorithm is shown in Figure 1.  
Angiographic assessment criteria 
Angiographic measurements were taken in the Axis Siemens cathlab (Siemens 
Medical Solutions Inc., Malvern, Pennsylvania) after intracoronary injection of isosorbide 
dinitrate. 
The following measurements were obtained: baseline TIMI flow, percentage stenosis on QCA 
(Quantitative Coronary Angiography: Siemens Quantcor, Siemens Medical Solutions), 
arterial reference segment diameter (mm), minimum arterial diameter (mm), and thrombus 
length (mm). For an occluded culprit artery, thrombus length was determined from the first 
angiogram after coronary reperfusion. 
Angiographic analysis was performed by 2 independent investigators who were not involved 
in the clinical procedures. Disagreements were resolved by adjudication from a third observer. 
OCT assessment criteria 
The technique of OCT acquisitions (Frequency Domain OCT, version C7XR, St Jude 
Medical Inc., Saint Paul, Minnesota) was in line with recent expert review documents22,23. 
OCT analysis focused on the presence of thrombus22,23; thrombus burden, based on its 
extension (thrombus area, longitudinal extension) and thrombus score22,23; reference segment 
lumen area; minimum lumen area; percentage area stenosis; and presence of plaque rupture or 
erosion. OCT analyses were performed by 2 independent investigators, specifically 
addressing the feasibility and interpretability of images of region of interest in each 
examination, and any procedure-related complications. 
Clinical assessment and follow-up  
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Follow-up included screening for MACE (death, recurrence of myocardial infarction or need 
for surgical or percutaneous revascularization) and functional assessment (recurrence of 
angina) on systematic 12-months’ post-procedural consultation.  
Statistics 
Statistical analysis was performed using Stata software, version 12 (StataCorp, 
College Station, TX, US). The tests were two-sided, with a type I error set at α=0.05. 
Quantitative parameters were presented as the mean ± standard deviation (SD) for each group 
and as the number of patients and associated percentages for categorical variables. 
Comparisons between groups were analysed using the Chi-squared or Fisher’s exact test for 
categorical variables followed by Marascuillo procedure, and by ANOVA or Kruskal-Wallis 
test (normality verified by Shapiro-Wilk test and homoscedasticity by Bartlett test) followed 
by appropriate post-hoc multiple comparisons test (Tukey-Kramer or Dunn) for quantitative 
variables. In second step, relations between different parameters and groups were improved 
considering the delay as a quantitative parameter (and not as three groups determined by 
clinical and statistical relevance). When appropriate, correlation coefficients (Pearson or 
Spearman) were used.  
RESULTS 
Population 
Of 852 all comer ACS patients treated in our hospitals between 1 January 2010 to 1 
November 2011, 101(11.8%) patients (53±13 years, 78% male; 94% STEMI, 6% NSTEMI) 
were included. These patients had a LTB in the culprit artery on initial angiography and were 
treated with aspiration thrombectomy. Twenty two percent of these patients were treated with 
pre-hospital thrombolysis. The clinical characteristics of the patients are shown in Table 1. 
Overall, 38 (38%) patients did not receive a stent in the culprit lesion and were treated 
medically.  
Angiography results 
 The results of the initial and subsequent angiograms are shown in Tables 1 and 2, 
respectively. OCT was performed at Days 0-2 (Group 1, including n=18 patients with 
immediate post-thrombectomy analysis), Days 3-6 (Group 2) or Days 7-30 (Group 3). 
Stenting was performed when the residual stenosis in the culprit lesion was >70% of the 
reference area or when there was evidence of plaque prolapse. Clinical follow-up lasted for 12 
months. 
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OCT results 
The OCT procedure was uncomplicated in all patients and all of the OCT recordings 
were of diagnostic quality (Table 3).  
Thrombus was revealed in 68.3% with OCT and 20.8% of patients with angiography 
alone. Thrombus burden diminished over time and was revealed by OCT in 94.1% of patients 
in Group 1, 78.8% of patients in Group 2 and 32.4% of patients in Group 3, with mean 
thrombus scores of 21.6, 13.6 and 4.2, respectively. Thus, maximum thrombus area and 
length also diminished over time with sequential increases in minimum lumen area and 
reduced percentage stenosis across the groups. Mean lesion length was 13.5 mm and was less 
than 15 mm in 70% of cases. 
Plaque rupture was disclosed by OCT in 66 patients (65.3%) (Figure 2). In these cases, 
fibrous cap thickness ranged from 30 to 210µm, for a median 73.6 µm. Plaque erosion was 
diagnosed in 25 patients in absence of thrombus or rupture : 22 of 25 patients with plaque 
erosion suspected were in the non immediate groups (n=7 in the G2 and n=15 in the G3). 
There were only 3 patients in the first group. In 10 other patients the shadow related to light 
attenuation by residual thrombus precluded diagnostic evaluation of the lesion: the diagnostic 
value of OCT is reduced in cases with red thrombus. 
Treatment and evolution 
The treatment and follow-up information are given in Table 3. All patients were 
treated by double anti-platelet therapy (DAP) and received low-molecular weight 
heparin anticoagulation during the initial hospital phase. LMWH was stopped when 
patients were discharged from the hospital. A total of 27 patients out of 101 were 
discharged from the hospital before the second angiography. 
Only 63 patients (62.4%) underwent coronary stenting and no complications occurred. 
The mean stent diameter was 3.40 +/- 0.6 mm and the mean length was 20.4 +/- 7.1 mm. In 
all 63 patients, only 1 stent was implanted per lesion, including 9 with bifurcation lesions that 
had been managed by provisional T-stenting. The other 38 patients were managed medically. 
None required coronary artery bypass graft. 
OCT was performed at the end of the procedure in all patients treated with PCI in 
order to assess the final stent results (Figure 3). There was evidence of limited (<1 mm) 
coronary edge dissection in 6 patients (9.5%). Malapposition was observed in 11 patients 
(17.5%) and intrastent protrusion in 45 (moderate [<500 µm] in 27 [48.5%] and significant 
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[>500 µm] in 18 [28.5%]). Post-stent arterial reference area was 9.28 +/- 3.19 mm2, with a 
mean reference diameter of 3.32 +/- 0.75 mm and minimum arterial area of 7.51 +/-3.52 mm2. 
The peak serum CPK ranged from 93 to 8,695 IU, with a median of 1,257. The mean 
left ventricle ejection fraction measured by echocardiography was 56.2% [37-80].  
Two MACEs events occurred (2%) during follow-up during 12 months follow-up. An 
71 year old man who had been managed medically experienced angina and had a clinically-
indicated elective angiogram which showed culprit lesion progression which was treated with 
a drug-eluting stent. An 83 year old man managed by angioplasty, showed non-fatal ischemic 
ACS at 8 months post-procedure. There were no cases of sudden death or of myocardial 
infarction. 
DISCUSSION 
 Our main finding is that using stratified management involving a staged approach with 
invasive management selectively guided by OCT combined with optimal anti-thrombotic 
therapy, nearly half of the ACS patients selected for this form of management were safely 
treated without a stent. In all, nearly 1/8th of all-comer ACS patients in our hospitals were 
selected for this treatment pathway. 
Our treatment algorithm was predicated on the use of optimal ant-thrombotic therapy 
to prevent coronary re-occlusion in patients who were not treated with a stent and high 
resolution intra-vascular imaging to stratify patients for stenting or not. We found that 1) 
sustained use of parenteral anti-thrombotic therapy was safe and not associated with bleeding 
problems, 2) staged repeated invasive management was safe, 3) OCT was feasible and safe in  
this setting, 3) OCT revealed thrombus burden and culprit lesion characteristics with superior 
resolution than angiography alone,4) OCT helped guide treatment decisions to stent or not (i.e. 
treat with medical therapy alone) and, 5) angiography underestimates thrombus burden, 
detecting 20.8% residual thrombus after thrombectomy, versus 68.3% on OCT.  
 Pathology studies by Virmani have shown that ACS are most often due to plaque 
rupture or erosion24; was and these observations have been subsequently confirmed on IVUS 
and on OCT24,26,27. Fibrous cap thickness is critical to onset of these complications, thickness 
<65 μm being associated with high risk of rupture28. The underlying stenosis is not 
necessarily tight, as the thrombotic component predominates in arterial occlusion. In case of 
LTB, stenting incurs a risk of no-flow, distal embolisation29,30 and malapposition. Kim, using 
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OCT31, showed that late stent malapposition and neointimal coverage defect were observed 
more frequently in ACS than in chronic angina.  
Historically, culprit lesion stenting has been the evidence-based standard of care for 
coronary artery disease amenable to PCI in ACS patients. However, several groups are re-
examining this approach, and new treatment strategies are now emerging. Isaaz’s32 2-step 
Minimalist Immediate Mechanical Intervention (MIMI) strategy consists in restoring TIMI-3 
flow in the acute phase and postponing stenting from D0 to D2-5 to allow optimization of the 
result or indeed reconsideration of indications. The modernContemporary antithrombotic 
regime therapy, including (glycoprotein IIb/IIIa inhibitor therapy, loading dose of dual 
antiplatelet drugss, and anticoagulation,) allows such a wait-and-seefacilitates the safety of an 
observational approach, minimizing the risk of early thrombosis. Jolicoeur’s recent meta-
analysis33 of 6 studies (5 non-randomized) found deferred stenting to be safe (3 coronary re-
occlusions before control, in 283 patients) and beneficial (improved LV function), with a 
lower 1-year MACE rate. The present study applied this 2-step strategy, with the interval to 
control (up to day 30) left at the operator’s discretion while awaiting optimal thrombectomy 
using anti-GPIIb/IIIa and/or thrombo-aspiration as often as possible (respectively, 76.2% and 
72.3% of cases). Results confirmed the feasibility and safety of this attitude: in 101 patients, 
there were no MACEs before angiogram 2, taken at a mean 9 days (median, 5 days).  
The presentOur study also confirmed that, in a setting of ACS, OCT was feasible, with 
no procedural complications in any of the 101 patients., OCT and provided consistently 
interpretable imagingdata. The new generation of OCT (OFDI: Optical Frequency Domain 
Imaging) is faster and easier simpler to perform34. OCT enables analysis not only of thrombus 
burden but also of the ACS-culprit lesion, for which Kubo15 demonstrated its superiority to 
angioscopy and IVUS: in this pilot study, OCT in the acute phase visualized thrombus in 100% 
of cases, plaque rupture in 73% and erosion in 23%. In 101 cases of ACS, the present study 
identified 66 plaque ruptures (65% of cases) with a mean cap thickness of 73 μm, and 22 
plaque erosions. 
Finally, OCT can guide treatment, optimizing stenting and sometimes indicates isolated 
medical therapy. By sometimes postponing angiographic control, more complete thrombus 
regression can be obtained, with improved assessment of the atheromatous component of the 
stenosis. Previous works highlighted the negative impact of high thrombus burden 
within the culprit lesion on short and long-term outcome during STEMI35 or NSTEMI36. 
Thrombectomy techniques can improve these results by dramatically reducing 
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thrombus load during ACS, but a complete disappearance is rarely obtained and real 
benefits of the technique have been recently challenged37. Following thrombectomy, if 
there is no significant stenosis, the indication for stenting can be reviewed. Plaque erosion and 
with a moderate stenosis may show spontaneous cicatrization healing, scar formation and re-
endothelialization of the arterial wall and: the favorable prognosis under optimal medical 
management seen onboth IVUS in such cases38 was recently confirmed onand OCT have 
provided information on plaque healing with medical therapyby Prati 27. Thirty-eight of the 
present 101 patients were managed medically, without stenting, (38%). At 12 months’ follow-
up, only 1 of the 38 showed evolution toward ischemic stenosis, requiring stenting at 6 
months. In the series as a whole, there were no acute events (ACS or sudden death). Previous 
studies investigated the feasibility of deferred PCI for STEMI treatment under optimal 
antithrombotic therapy, on the basis of angiographic findings only 39,40. These series reported 
that this procedure could be performed safely in selected patients and also induced a 
decreased rate of culprit lesion stenting. Hence, Echavarria-Pinto and colleagues observed 
that stenting could be avoided in 29.2% of their patients, which is comparable to the present 
data. However, the real impact of culprit lesion OCT analysis on the need for stent remains 
difficult to assess, as we do notsince our study did not include have an angiography-only 
control group of patients treated by angiography analysis alone, further randomised controlled 
studies are needed to assess the influence of OCT-guided treatment decisions for stenting or 
not of culprit lesions. . This point was out of the range of the present pilot study but could be 
investigated in future randomized trials. 
OCT-guided postponement optimised stenting:of stent implantation was associated with good 
procedural outcomes: 100% success and no no-reflow events. The rate of malapposition was 
relatively low, at 17.5%, despite ACS being a known factor for malapposition31. Thrombus 
reduction allows stent diameter and length to be tailored to the lesion, minimizing the risk of 
restenosis. The stents deployed were wider (3.4+/-0.6mm) than initial QCA (mean reference 
diameter = 3.22+/-0.59) would have indicated. Finally, postponement reduced the rate of 
bifurcation stenting: initial angiography implicated bifurcations in 36% of cases, whereas only 
9% of patients actually needed bifurcation stenting. 
 What is the optimal interval for the OCT ‘control’ imaging in the 2-step management 
of ACS? Analyzing the 3 tertiles for the control imaging interval shows that thrombus burden 
tends to decrease over time on whatever criteria:according to thrombus length, maximum area 
or score. This reduction is associated with increased minimum lumen area and reduced 
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percentage stenosis. This may account for the significantly reducedlower rate of stenting in 
the late-OCT group (Figure 4). 
 
Study limitations 
The main limitation of this study was the non-randomized design meaning we cannot draw 
conclusions about the influence of OCT over angiography alone on treatment decisions or 
clinical outcomes. Moreover the timing of OCT procedure was empirically decided by the 
operator until 1 month. Our study was neither designed nor powered for a health outcome 
analysis. The study population included selected patients during routine clinical care 
(approximately 15% of all ACS cases admitted during the study period). Therefore, the 
conclusions in our study are relevant to patients with a large thrombus burden at initial 
angiography and should not be extrapolated to all-comer ACS patients especially where initial 
thrombus burden is light. Moreover, patients from Group 1 underwent early OCT analysis: 
although white thrombus (that induces minimal backscattering attenuation) was identified in 
the vast majority of the cases, residual large thrombus burden might have affected the analysis 
of the underlying plaque morphology. Hence, this factor could potentially explain the lowest 
incidence of plaque rupture/erosion identified in these patients compared to the others and 
advocates for the need of delaying the OCT control from the acute event in order to properly 
assess the underlying morphology of ACS culprit lesions. Finally, the appropriated  OCT 
criteria to decide whether the culprit lesion should be stented or not are not validated in 
the settings ofin ACS and STEMIpatients remains to be determined. Importantly, 
overall, stenting of culprit lesions represents the overall standard of care. In our 
study,We used a ratio between reference lumen area and minimum lumen area (MLA) 
to tailor PCI. use in this clinical situation that could be debatable.   
Our proof-of-concept study was designed to assess feasibility and safety and a larger 
substantive trial will be needed to evaluate the role of OCT-guided treatment decisions in 
ACS patients with large thrombus burden. A randomised trial with surrogate health outcomes, 
such as with MRI for infarct size at 30 days, may be the next logical step.  
CONCLUSION 
OCT in ACS is feasible and complication-free. The present study demonstrated 
improved assessment of thrombus burden, which angiography tends to underestimate, and 
improved culprit-lesion analysis. 
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Following maximal thrombectomy, OCT allowed abstention from stenting in 38% of cases in 
this pilot study on a selected population. When indicated, stenting was reliable and perhaps 
better adapted to culprit-lesion morphology.  
We believe Aa randomised controlled trial including of an OCT-guided invasive strategy in 
the management of ACS patients with LTB should determine the role of this technique in 
these indications. 
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Figure legends 
Figure 1: Decision and treatment tree 
Figure 2 : Five examples of young patients (<50 years) included in the study: angiographies 
(A,B,C,D,E) at baseline (top) and after thrombectomy (bottom); OCT frames after 
thrombectomy (A’,B’,C’,D’,E’) of the culprit lesion (top) and reference segment (bottom). 
Only C, D and E were stented, for residual stenosis >70% or plaque prolapse. 
Figure 3 : Baseline angiography (A) in a 37 year-old female treated by thrombus aspiration 
and GPIIb/IIIa inhibitors. Angiography 30 days later, before (B) and after stenting (C). OCT 
frames of culprit lesion (B1) and reference segment (B2), minimum lumen area (MLA) <30% 
reference lumen area (RLA). Post-stenting OCT frames showing optimal strut apposition 
without thrombus protrusion (C1). 
Figure 4: Thrombotic score (gray boxes) and stenting rate (white boxes) in each group: acute 
(D0 to D2), early (D3 to D6) and late OCT (D7 to D30). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
